Patents Assigned to Acorda Therapeutics
-
Publication number: 20240050376Abstract: The present invention generally relates to sustained release 4-aminopyridine tablets, which include a core and a coating. The sustained release tablets of the invention are generally suitable for once daily oral administration for the treatment of neurological disorders.Type: ApplicationFiled: October 17, 2023Publication date: February 15, 2024Applicant: Acorda Therapeutics, Inc.Inventors: Joseph E. Cobb, JR., Thomas B. Gold, Rohini D'Souza, Susan L. Way
-
Publication number: 20240041850Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.Type: ApplicationFiled: October 9, 2023Publication date: February 8, 2024Applicant: Acorda Therapeutics, Inc.Inventors: Andrew R. Blight, Ron Cohen
-
Publication number: 20230390261Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.Type: ApplicationFiled: August 23, 2023Publication date: December 7, 2023Applicant: Acorda Therapeutics, Inc.Inventors: Andrew R. Blight, Ron Cohen
-
Publication number: 20230133230Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.Type: ApplicationFiled: December 29, 2022Publication date: May 4, 2023Applicant: Acorda Therapeutics, Inc.Inventors: Andrew R. Blight, Ron Cohen
-
Publication number: 20220323362Abstract: The present invention generally relates to sustained release 4-aminopyridine tablets, which include a core and a coating. The sustained release tablets of the invention are generally suitable for once daily oral administration for the treatment of neurological disorders.Type: ApplicationFiled: November 19, 2021Publication date: October 13, 2022Applicant: Acorda Therapeutics, Inc.Inventors: Joseph E. Cobb, JR., Thomas B. Gold, Rohini D'Souza, Susan L. Way
-
Publication number: 20220296577Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.Type: ApplicationFiled: June 2, 2022Publication date: September 22, 2022Applicant: Acorda Therapeutics, Inc.Inventors: Andrew R. Blight, Ron Cohen
-
Publication number: 20220040161Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.Type: ApplicationFiled: October 26, 2021Publication date: February 10, 2022Applicant: Acorda Therapeutics, Inc.Inventors: Andrew R. Blight, Ron Cohen
-
Patent number: 11235031Abstract: The invention relates to treatment of heart failure in a mammal. Accordingly, the invention is directed to establishing a dosing regimen whereby the therapeutic benefits conferred by administration of a neuregulin such as glial growth factor 2 (GGF2) or a subsequence thereof are maintained and/or enhanced, while concomitantly minimizing any potential side effects.Type: GrantFiled: September 9, 2019Date of Patent: February 1, 2022Assignee: Acorda Therapeutics, Inc.Inventors: Anthony O. Caggiano, Anindita Ganguly, Jennifer Iaci, Tom Parry
-
Publication number: 20210338590Abstract: The present invention generally relates to sustained release 4-aminopyridine tablets, which include a core and a coating. The sustained release tablets of the invention are generally suitable for once daily oral administration for the treatment of neurological disorders.Type: ApplicationFiled: July 13, 2021Publication date: November 4, 2021Applicant: Acorda Therapeutics, Inc.Inventors: Joseph E. Cobb, JR., Thomas B. Gold, Rohini D'Souza, Susan L. Way
-
Patent number: 11141467Abstract: A method for modifying access of cells to extravascular spaces and regions comprising administering to a patient an enzyme that cleaves chondroitin sulfate proteoglycans is provided. It has been found that administration of an enzyme that cleaves chondroitin sulfate proteoglycans to a patient disrupts extravasation of cells from the blood stream into tissue. The present invention provides methods of reducing penetration of cells associated with inflammation into tissue of a patient. Several methods are also provided for the regulation and suppression of inflammation comprising administering enzymes that digest chondroitin sulfates. Also provided are methods of treating and preventing inflammation associated with infection, injury and disease.Type: GrantFiled: July 17, 2017Date of Patent: October 12, 2021Assignee: Acorda Therapeutics, Inc.Inventors: Elliott A. Gruskin, Jack L. Tseng, Anthony O. Caggiano
-
Patent number: 11136342Abstract: The present invention provides carbonate prodrugs which comprise a carbonic phosphoric anhydride prodrug moiety attached to the hydroxyl or carboxyl group of a parent drug moiety. The prodrugs may provide improved physicochemical properties over the parent drug. Also provided are methods of treating a disease or condition that is responsive to the parent drug using the carbonate prodrugs, as well as kits and unit dosages.Type: GrantFiled: July 1, 2019Date of Patent: October 5, 2021Assignee: Acorda Therapeutics, Inc.Inventors: Naweed Muhammad, Keith R. Bley
-
Publication number: 20210251974Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.Type: ApplicationFiled: May 4, 2021Publication date: August 19, 2021Applicant: Acorda Therapeutics, Inc.Inventors: Andrew R. Blight, Ron Cohen
-
Patent number: 11071770Abstract: The present invention relates to a method for detecting heart damage in a patient. The invention also relates to methods for treatment of patients identified as having heart damage. The invention further pertains to methods for evaluating the efficacy of an ongoing therapeutic regimen designated to treat a damaged heart in a patient.Type: GrantFiled: March 20, 2019Date of Patent: July 27, 2021Assignee: Acorda Therapeutics, Inc.Inventors: Xinhua Yan, Anthony O. Caggiano
-
Publication number: 20210205282Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.Type: ApplicationFiled: March 16, 2021Publication date: July 8, 2021Applicant: Acorda Therapeutics, Inc.Inventors: Andrew R. Blight, Ron Cohen
-
Patent number: 11021498Abstract: The present invention provides water-soluble acetaminophen prodrugs and formulations which may be suitable for parenteral administration. Methods of treating a disease or condition responsive to acetaminophen (such as fever and/or pain) using the acetaminophen prodrugs, as well as kits, unit dosages, and combinations with additional pharmaceutical agent(s) are also provided.Type: GrantFiled: September 9, 2019Date of Patent: June 1, 2021Assignee: Acorda Therapeutics, Inc.Inventors: Naweed Muhammad, Keith R. Bley
-
Publication number: 20210085614Abstract: The present invention generally relates to sustained release 4-aminopyridine tablets, which include a core and a coating. The sustained release tablets of the invention are generally suitable for once daily oral administration for the treatment of neurological disorders.Type: ApplicationFiled: December 4, 2020Publication date: March 25, 2021Applicant: Acorda Therapeutics, Inc.Inventors: Joseph E. Cobb, Jr., Thomas B. Gold, Rohini D'Souza, Susan L. Way
-
Publication number: 20210008051Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.Type: ApplicationFiled: September 22, 2020Publication date: January 14, 2021Applicant: Acorda Therapeutics, Inc.Inventors: Andrew R. Blight, Ron Cohen
-
Publication number: 20200368217Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.Type: ApplicationFiled: August 12, 2020Publication date: November 26, 2020Applicant: Acorda Therapeutics, Inc.Inventors: Andrew R. Blight, Ron Cohen
-
Publication number: 20200253880Abstract: The present invention generally relates to sustained release 4-aminopyridine tablets, which include a core and a coating. The sustained release tablets of the invention are generally suitable for once daily oral administration for the treatment of neurological disorders.Type: ApplicationFiled: March 23, 2020Publication date: August 13, 2020Applicant: Acorda Therapeutics, Inc.Inventors: Joseph E. Cobb, JR., Thomas B. Gold, Rohini D'Souza, Susan L. Way
-
Publication number: 20200230121Abstract: Disclosed herein is use of one or more aminopyridines in methods and compositions for treatment of impairments in gait or balance in patients with multiple sclerosis.Type: ApplicationFiled: April 8, 2020Publication date: July 23, 2020Applicant: Acorda Therapeutics, Inc.Inventors: Gabriel Pardo, Gustavo Adolfo Suarez Zambrano, Cecilie Fjeldstad